|
Post by guruzim on Jun 8, 2015 6:04:12 GMT
Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold(TM) (Migalastat) in European Union
MAA Submission Under "Accelerated Assessment"
Brand Name Galafold(TM) Approved by Regulatory Authorities in EU and U.S.
CRANBURY, N.J., June 3, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has submitted a marketing authorization application (MAA) to request full approval of the oral small molecule pharmacological chaperone Galafold (migalastat HCl) for Fabry patients who have amenable genetic mutations. The brand name Galafold has been approved by both the European Medicines Agency (EMA) as well as the U.S. Food and Drug Administration (FDA).
"This filing represents the single greatest milestone in the history of Amicus," stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics. "The MAA submission for Galafold is the first marketing application for Amicus. This comprehensive regulatory submission is the result of the tireless efforts of so many Amicus employees, investigators, consultants and, most importantly, the Fabry patients who have volunteered to participate in our clinical trials over the years. Our goal now is crystal clear: to bring this novel small molecule, orally bioavailable personalized medicine to as many people living with this devastating genetic disease as quickly as possible. We could not be more proud of our team and thankful to the entire Fabry community as we are today."
|
|
|
Post by JHam on Jun 8, 2015 6:23:54 GMT
Amicus Therapeutics Submits Marketing Authorization Application (MAA) for Full Approval of Fabry Monotherapy Galafold(TM) (Migalastat) in European Union MAA Submission Under "Accelerated Assessment" Brand Name Galafold(TM) Approved by Regulatory Authorities in EU and U.S. CRANBURY, N.J., June 3, 2015 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has submitted a marketing authorization application (MAA) to request full approval of the oral small molecule pharmacological chaperone Galafold (migalastat HCl) for Fabry patients who have amenable genetic mutations. The brand name Galafold has been approved by both the European Medicines Agency (EMA) as well as the U.S. Food and Drug Administration (FDA). "This filing represents the single greatest milestone in the history of Amicus," stated John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics. "The MAA submission for Galafold is the first marketing application for Amicus. This comprehensive regulatory submission is the result of the tireless efforts of so many Amicus employees, investigators, consultants and, most importantly, the Fabry patients who have volunteered to participate in our clinical trials over the years. Our goal now is crystal clear: to bring this novel small molecule, orally bioavailable personalized medicine to as many people living with this devastating genetic disease as quickly as possible. We could not be more proud of our team and thankful to the entire Fabry community as we are today." Thanks for posting this. I saw this the other day and meant to post it then forgot. It is a huge deal for Amicus and Fabry patients. I don't own any of this anymore and don't plan to at the moment, as I am not sure how much higher than $1.2B (current market cap) the Fabry market can take this. FOLD is one of the most successful stocks for me, as I did pretty well trading this one over the past 3 years. It is the perfect model of the kind of company that I love where they have lots of cash on hand, but become extremely undervalued due to the market's misunderstanding of data, (a la TNXP, NRIFF, and to some extent ATHX). Once the market figures out they made a mistake it has a potential to skyrocket.
|
|
|
Post by guruzim on Jun 8, 2015 16:47:41 GMT
I don't see a quick run up, but I've got my shares tucked away in my Roth as one of my "never sell" investments. I unfortunately took my initial investment out when it doubled up so these are my profit shares. Just something to sit on and see where it goes.
Hopefully Galafold is the drug that funds further ERT research. They just picked up two execs today (A CSO and someone from Biogen) so they appear to be ramping things up.
|
|
|
Post by JHam on Jun 8, 2015 17:24:41 GMT
I don't see a quick run up, but I've got my shares tucked away in my Roth as one of my "never sell" investments. I unfortunately took my initial investment out when it doubled up so these are my profit shares. Just something to sit on and see where it goes. Hopefully Galafold is the drug that funds further ERT research. They just picked up two execs today (A CSO and someone from Biogen) so they appear to be ramping things up. I think FOLD is a really solid company and I like Crowley. They have other potential in the pipeline besides Fabry. If they follow the same path as Fabry then I think there is still some good long term potential from here, and of course brining in any revenue from Migalastat will add more value. Just at the moment, as I have said to an annoying extreme, I am more interested in super undervalued companies.
|
|